Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2021

View Archived Issues

Second interim analysis data from phase IIa study of vilobelimab in pyoderma gangrenosum

Resveratrol-triggered switches maximize cancer immunotherapy, reduce toxicity

Final topline data presented from DeCidE1 study of MVP-S in ovarian cancer

New PSMB8 inhibitors divulged by Shouyao Holdings

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents BCR-ABL inhibitors

New MAP4K1 inhibitors identified at Blueprint Medicines

Mindset presents preclinical data for next-generation psychedelic drug families

Beta Pharma synthesizes new FGFR inhibitors

aTyr expands its research collaboration with Ohio State University

Positive interim data presented from phase I study of FTX-6058

Anti-PRNP monoclonal antibody decreases tau pathology in mouse Alzheimer's disease model

Kaleido and COPD Foundation collaborate to advance development of KB-109

Skye completes IND-enabling genotoxicity studies for THCVHS

Rezolute initiates phase Ib study of RZ-402 for DME

Goldfinch Bio initiates dosing in extension study of GFB-887 for patients with FSGS

Recombinant human NAGLU coexpressing S1S3 phosphotransferase developed for Sanfilippo B syndrome

China's NMPA approves IND for phase I/II study of BBM-H901

Positive topline data from phase Ia/Ib trial of CB-4211

InnoCare receives NMPA clearance for phase II study of orelabrutinib in ITP

CRN-04894 shows pharmacologic proof of concept in phase I study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...